Zepbound and Mounjaro contain the same active ingredient—tirzepatide—but they are approved for different purposes. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The dosing protocols are similar, but insurance coverage rules differ significantly. At PEAK, we prescribe Zepbound for weight loss when clinically appropriate, never off-label Mounjaro.
Side-by-side comparison
This table outlines the key differences between these two tirzepatide formulations.
| Zepbound | Mounjaro | |
|---|---|---|
| Active ingredient | Tirzepatide (dual GIP/GLP-1 agonist) | Tirzepatide (dual GIP/GLP-1 agonist) |
| FDA approval | Chronic weight management (obesity/overweight) | Type 2 diabetes management |
| Max dose | 15 mg weekly | 15 mg weekly |
| Typical titration | 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg | 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg |
| Pen design | Single-dose pre-filled pen (4 doses per box) | Single-dose pre-filled pen (4 doses per box) |
| Insurance for weight loss | Covered by many plans (with prior authorization) | Not covered for weight loss; requires diabetes diagnosis |
| Typical cash price | high out-of-pocket pricing | high out-of-pocket pricing |
| Clinical trial focus | SURMOUNT trials (weight management) | SURPASS trials (diabetes management) |
Note: Both medications are manufactured by Eli Lilly. Prices reflect list prices without insurance or manufacturer savings programs.
What makes tirzepatide different from semaglutide
Tirzepatide is not just a GLP-1 receptor agonist—it's a dual agonist. It activates both GLP-1 receptors (like semaglutide) and GIP receptors (glucose-dependent insulinotropic polypeptide). This dual mechanism may produce greater weight loss and improved glycemic control compared to GLP-1-only medications, though individual responses vary.
In the SURPASS-2 trial (tirzepatide vs. semaglutide for diabetes), patients on the highest tirzepatide dose lost an additional 1–2% of body weight compared to semaglutide 1 mg at 40 weeks. For a dedicated weight-loss head-to-head, the SURMOUNT-5 trial (2025) compared tirzepatide to semaglutide 2.4 mg and found 20.2% vs. 13.7% body weight loss over 72 weeks. This doesn’t mean tirzepatide is universally “better”—it means the dual GIP/GLP-1 mechanism produces greater average weight reduction, though individual responses vary.
From a clinical standpoint, the dual-agonist mechanism is why tirzepatide is sometimes considered for patients who have plateaued on semaglutide or who need additional metabolic support. But the choice between these medications is not just pharmacology—it's also about insurance coverage, side effect tolerance, and individual treatment goals.
Different FDA approvals mean different prescribing rules
Mounjaro received FDA approval in May 2022 for adults with type 2 diabetes to improve glycemic control. It demonstrated significant A1C reductions and cardiovascular risk benefits in the SURPASS clinical trial program. Weight loss was a consistent secondary finding but not the primary therapeutic indication.
Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It must be used alongside reduced-calorie diet and increased physical activity.
Like the Wegovy/Ozempic distinction, the molecule is identical—but the FDA approval, intended use, and insurance billing codes are different. Prescribing Mounjaro off-label for weight loss in a patient without diabetes creates insurance coverage issues and raises clinical documentation concerns.
Same molecule. Different indications. Different coverage pathways. The regulatory distinction is not arbitrary—it shapes how treatment is accessed and paid for.
Insurance coverage: why Zepbound requires prior authorization
Most insurance plans that cover GLP-1 and GIP/GLP-1 medications for weight loss will cover Zepbound—but they require prior authorization. Your clinician must submit documentation proving you meet medical necessity criteria: BMI thresholds, documented comorbidities, and evidence of lifestyle intervention.
Mounjaro, by contrast, is typically covered for patients with type 2 diabetes without prior authorization (though some plans still require it). If you do not have diabetes and your clinician prescribes Mounjaro for weight loss, your insurance will likely deny the claim.
Some patients ask whether they can use Mounjaro "off-label" and pay cash to avoid insurance complications. This is possible, but it creates issues: (1) you lose access to manufacturer savings programs designed for Zepbound, (2) off-label prescribing may complicate future insurance appeals if you later seek coverage for Zepbound, and (3) the dosing and monitoring protocols are optimized for the FDA-approved indication.
At PEAK, we prescribe the medication that matches your diagnosis and your insurance plan's coverage rules. If you qualify for weight loss treatment, we prescribe Zepbound and handle the prior authorization process. We do not prescribe Mounjaro off-label for weight management.
Which one is right for you?
The decision is driven by your diagnosis and your insurance plan's formulary, not by personal preference or marketing.
You'll likely receive Mounjaro if:
You have a diagnosis of type 2 diabetes, and your clinician determines a GLP-1 medication is appropriate for glycemic control. Weight loss may occur as a secondary benefit, but the primary goal is managing your blood sugar and reducing cardiovascular risk.
You'll likely receive Zepbound if:
You meet the BMI criteria for chronic weight management (with or without comorbidities) and do not have diabetes—or you have diabetes but your clinician is prescribing specifically for weight loss as the primary indication. Zepbound is the FDA-approved option for this purpose.
What if you have both obesity and diabetes?
This is a clinical judgment call. Your clinician may prescribe Mounjaro to address diabetes (with weight loss as a beneficial side effect) or Zepbound to address obesity (with improved glycemic control as a side effect). The choice depends on which condition is the primary treatment target and which medication your insurance plan covers.
In either case, the medication is the same molecule. What changes is the approval pathway, the billing code, and the insurance coverage rules your clinician manages on your behalf.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
